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SUMMARY
Testicular germ cell tumors (TGCT) are the most common malignant neoplasm in young men. DNA mismatch repair deficiency
can lead to microsatellite instability (MSI), an important mechanism of genetic instability. A mutation of the BRAF gene has been
implicated in the pathogenesis of several solid tumors and has recently become an important therapeutic target. The role of MSI and
BRAF gene mutation in TGCT, particularly in refractory disease, is poorly understood and reported findings are controversial. In this
study, we aimed to determine the frequency and clinical impact of MSI status and BRAF mutations in TGCT. DNA was isolated from
formalin-fixed paraffin embedded (FFPE) tissue from 150 TGCT cases. The MSI phenotype was evaluated using multiplex PCR for
five quasimonomorphic mononucleotide repeat markers. Exon 15 of the BRAF oncogene (V600E) was analyzed by PCR, followed by
direct sequencing. Sixteen percent of cases were considered to have refractory disease. In a small subset of cases (17 for MSI and 18
for BRAF), the quantity and quality of DNA recovery were poor and therefore, were unable to be analyzed. The remaining 133 TGCT
cases showed a complete absence of MSI. Of the 132 cases successfully evaluated for BRAF mutations, all were V600E wild-type. In
conclusion, despite a distinct response of testicular germ cell tumors to therapy, microsatellite instability, and the BRAF V600E muta-
tion were absent in all testicular germ cell tumors tested in this study.
INTRODUCTION
Testicular germ cell tumors (TGCT) are the most frequent
malignant neoplasm found in young men and represent 95% of
testicular cancers (Bray et al., 2006). Commonly, TGCTs are clas-
sified into two distinct groups, seminomas (SE) and non-semi-
nomas (non-SE). The mainstay treatment for both over the last
few decades has been platinum-based chemotherapy and sur-
gery, leading to robust response and cure rates (Einhorn, 2002;
Feldman, 2015). Patients with advanced disease achieve a 5-
year-overall survival of more than 70% (Ries et al., 2007), while
those with non-SE have a poorer prognosis and 5-year-overall
survival of 50% (IGCCCG, 1997). Fifteen percent of all patients
will develop refractory disease representing a challenge in the
clinical management (Mead et al., 2005; Lorch et al., 2010).
The integrity of the genome depends on the coordinated
action of DNA repair genes, also known as ‘caretakers’ (Kinzler &
Vogelstein, 1997). The failure of one type of such caretakers, a
DNA mismatch repair gene, contributes to genome instability by
making microsatellite regions more susceptible to mismatch,
leading to what is termed microsatellite instability (MSI) (Imai &
Yamamoto, 2008; Shah et al., 2010). The MSI phenotype is a hall-
mark of hereditary non-polyposis colorectal cancer (HNPCC)
syndrome, but is also present in 10–15% of sporadic colorectal
cancers (Kinzler & Vogelstein, 1996; Hamelin et al., 2008; Gryfe,
2009). MSI phenotype has also been described in other cancers
including endometrial and gastric (Hamelin et al., 2008).
Recently, colorectal and non-colorectal tumors with identified
mismatch-repair defects have been reported as more responsive
to a new anti–programmed death 1 immune checkpoint inhibi-
tor drug, highlighting a new role for MSI in immunotherapeutic
prediction (Le et al., 2015).
The BRAF oncogene is an important part of the MAPK (Mito-
gen Activated Protein Kinase) cellular signaling pathway and
related to cell proliferation, differentiation and survival (Kolch,
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2000). BRAF is activated by hotspot mutations, mainly V600E,
which has been found in melanomas and other types of cancer
(Rajagopalan et al., 2002; Michaloglou et al., 2008). Recently, the
BRAF V600E mutation has emerged as a therapeutic target in
melanoma, changing the natural history of the disease (Chap-
man et al., 2011).
In TGCT, the roles of MSI and BRAF mutations are poorly
characterized and controversial results have been reported
(Huddart et al., 1995; Mayer et al., 2002; Velasco et al., 2004,
2008; Sommerer et al., 2005; Honecker et al., 2009; Masque-
Soler et al., 2011). Therefore, in the present study, we evaluated
the presence and clinical impact of MSI and BRAF mutations in
a large series of TGCTs.
MATERIALS ANDMETHODS
Patients and specimens
Formalin-fixed paraffin-embedded (FFPE) tissues from 150
consecutive cases of testicular germ cell tumors were retrieved
from the Biobank of the Departments of Pathology at Barretos
Cancer Hospital (Brazil) and Hospital de Braga (Portugal). All
patients were diagnosed between 2006 and 2012 and all analyzed
samples were collected from primary tumors at diagnosis prior
to the use of any systemic treatment. All TGCT cases were inde-
pendently re-evaluated by a pathologist for diagnosis
confirmation.
Germ cell tumor cell lines
The germ cell tumor cell lines NTERA-2, 1411H, 1777N and
N2102Ep Clone2/A6 were purchased from the European Collec-
tion of Cell Cultures (ECACC). Cell lines were cultured in DMEM
containing 2 mM glutamine and 10% FBS (Sigma Aldrich, St.
Louis, MO, USA). After achieving 80% confluence, cell lines were
trypsinized, washed twice with 1% PBS, and centrifuged. DNA
was isolated using the TRIZOL reagent (Life Technologies,
Bethesda, MD, USA) and manufacturer’s recommendations
were followed.
DNA isolation from FFPE tissue
DNA was obtained from FFPE tissue sections representative of
tumor pathology as previously described (Martinho et al., 2009a,
b; Yamane et al., 2014), with minor modifications. Briefly, 10 lm
thick unstained sections of paraffin blocks were sectioned and
one H&E section was used for identification and selection of the
tumor area, which was then macrodissected into a microfuge
tube using a sterile needle (Neolus, 25G – 0.5 mm). The
macrodissected tissue was deparaffinized by a serial wash with
xylol and ethanol (100–70–50%) and allowed to air-dry. DNA was
isolated using the QIAamp DNA Micro Kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. The quality
and concentration of DNA were measured using a Nanodrop
2000 Spectrophotometer and stored at 20 °C until molecular
analysis.
Microsatellite instability analysis
Microsatellite instability evaluation was performed using
multiplex PCR for five quasimonomorphic mononucleotide
repeat markers (NR-27, NR-21, NR-24, BAT-25, and BAT-26) as
previously described (Viana-Pereira et al., 2011; Campanella
et al., 2014; Yamane et al., 2014). Briefly, each antisense primer
was end-labeled with a fluorescent dye: FAM (6-carboxyfluores-
cein) for BAT-26 and NR-21, VIC (20-chloro-70-phenyl-1,4-
dichloro-6-carboxyfluorescein) for BAT-25 and NR-27, and
NED (2,7,8-benzo-5-fluoro-2,4,7-trichloro-5-carboxyfluorescein)
for NR-24. PCR was performed using the Qiagen Multiplex PCR
Kit (Qiagen) with 0.5 lL of DNA at 50 ng/lL. All five markers
were co-amplified in a standard multiplex PCR (denaturation
at 95 °C for 15 min, 40 cycles of denaturation at 95 °C for
30 sec, annealing at 55 °C for 90 sec and extension at 72 °C for
30 sec, followed by a final extension at 72 °C for 40 min). PCR
products were then submitted to capillary electrophoresis on
an ABI 3500xL Genetic Analyzer (Applied Biosystems, Austin,
TX, USA) according to the manufacturer’s instructions. Results
were analyzed using GENEMAPPER v4.1 (Applied Biosystems)
software.
In a recent study, our group determined the quasimonomor-
phic variation range (QMVR) of each marker for the Brazilian
population (Campanella et al., 2014). Accordingly, samples were
considered MSI-H when two or more markers were altered and
MSI-low (MSI-L) when only one marker was altered, with further
validation by MSI analysis of normal tissue or immunohisto-
chemistry of the mismatch repair (MMR) enzymes. Samples
were considered microsatellite stable (MSS) when none of the
markers were altered.
The HCT-15 colorectal cancer cell line was used as a positive
control of MSI-High (MSI-H) in all MSI analyses. DNA from
HCT-15 cells was extracted using the TRIZOL reagent (Life Tech-
nologies) following the manufacturer’s protocol.
In 10% of samples, the MSI analysis was repeated for quality
control.
Mutational analysis of BRAF
Hotspot regions (exon 15) of the oncogene BRAF (codon
600) were analyzed by polymerase chain reaction (PCR), fol-
lowed by direct sequencing, as previously described by our
group (Basto et al., 2005; Martinho et al., 2009a,b; Yamane
et al., 2014).
Polymerase chain reactions were performed in a final volume
of 15 lL, according the following conditions: 1.5 lL buffer (Qia-
gen); 2 mM MgCl2 (Qiagen); 100 mM dNTPs (Invitrogen, Carls-
bad, CA, USA); 0.3 mM of both sense and anti-sense primers
(Sigma Aldrich), 1 unit of HotStarTaq DNA polymerase (Qiagen)
and 1 lL of DNA. The BRAF primers used were: 50-TCA-
TAATGCTTGCTCTGATAGGA-30 (sense) and 50-GGCCAAAAATT-
TAATCAGTGGA-30 (antisense) (Basto et al., 2005; Martinho
et al., 2009a,b; Yamane et al., 2014). The PCR was performed
with a Veriti thermocycler (Applied Biosystems) and products
were evaluated by electrophoresis in 1% agarose gel.
All PCR products were purified with EXO-SAP (GE Techonol-
ogy, Cleveland, OH, USA), and submitted for a sequencing reac-
tion using 1 lL of BigDye (Applied Biosystems), 1.5 lL of
sequencing buffer (Applied Biosystems) and 1 lL of primer.
Sequencing reactions were followed by post-sequencing purifi-
cation with EDTA, alcohol and sodium citrate. PCR products
were eluted in Hi-Di (formamide) and incubated at 95 °C for
5 min and subsequently cooled at 4 °C for at least 5 min.
Direct sequencing was performed on an ABI 3500 series Genetic
Analyzer (Applied Biosystems).
In 10% of samples, the BRAF mutation analysis was repeated
for quality control.
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Statistical analysis
We assessed measurements of frequency, central tendency,
and dispersion for clinical and pathological characteristics. The
overall survival was assessed using Kaplan–Meier methods. All
diagnostics were performed by orchidectomy before any sys-
temic therapy. Date of diagnosis was the starting point for the
survival analysis and events were defined as all-cause mortality.
Patients lost to follow-up or alive at the time of this analysis were
censored. Survival curves were compared using Logrank tests.
The two-sided p-values were considered statistically significant
at <0.05. All statistical analyses were performed using SPSS 19.0
software (IBM Corp, Armonk, NY, USA).
RESULTS
One hundred and fifty cases of TGCT were retrieved. After
DNA isolation, 17 cases of MSI and 18 cases of BRAF yielded
inconclusive results as a result of poor quality and quantity of
extracted DNA. The clinicopathological features of all validated
cases are summarized in Table 1.
The mean age of diagnosis was 30 years old and the majority
of cases (~68%) had non-SE. The predominant histologies
identified were mixed tumor followed by seminoma. All stages of
disease were observed, while advanced disease was the most fre-
quent stage identified. Among those who received chemother-
apy, around 16% were considered to have refractory disease
after treatment with the first-line chemotherapy regimen, BEP
(Bleomicine, Etoposide and Cisplatin). A majority of cases were
classified as having intermediate or high-risk disease according
to IGCCCG. Median follow-up was 36.0 months for cases evalu-
ating MSI and 35.5 months for BRAF evaluated cases. Five-year
overall survival was 84.5 and 83.2% for MSI and BRAF evaluated
cases, respectively.
Among treatment-refractory patients, the mean age was 29
(min: 20 years and max: 51 years) and 87% of tumors were non-
SE. A single case was categorized as stage II, while all other cases
were stage III. Eighty-five percent of valid cases presented with
two or more sites of metastasis and 95% were classified as high
or intermediate risk according IGCCCG (data not shown).
The overall survival of responsive and refractory patients to
chemotherapy in the cases evaluated for MSI or BRAF mutation
are demonstrated in Fig. 1A and B, respectively. Refractory cases
had a poorer overall survival rate compared to responsive cases.
We obtained results of MSI status for 88.7% (133/150) of
patients. 126 had a microsatellite stable (MSS) genotype, 7 had
MSI-L and none had MSI-H. In a previous study (Campanella
et al., 2014), our group reported that in order to accurately deter-
mine MSI-L, the MSI markers of tumor tissue should be com-
pared with the germ-line tissue of the patient. Therefore, for the
seven cases with MSI-L, we isolated adjacent normal tissue and
identified the presence of an identical MSI marker profile,
thereby indicating a MSS phenotype.
The mutation analysis of BRAF V600E was successful in 88%
(132/150) of TGTC cases. None were determined to have a BRAF
V600E mutation.
All germ cell tumor cell lines were observed to have MSS and
wild type BRAF.
DISCUSSION
In our study, we demonstrated an absence of MSI in all TGCT
analyzed even in the refractory cases and cell lines. These results
are in accordance with several studies, which also did not
observe such alterations in TGCT (Lothe et al., 1995; Faulkner &
Friedlander, 2000; Olasz et al., 2005; Vladusic et al., 2014)
(Table 2). In contrast, another study reported the presence of
MSI at a significant frequency (33%) and as a potential biomar-
ker of refractory TGCT and poor clinical outcome (Mayer et al.,
2011). Several factors may explain this discrepancy, including
differences in methodology, tumor subtype, and ethnically dis-
tinct populations. Indeed, the data are still controversial, with
MSI frequencies varying from 0 to 33%, and assessing a limited
number of cases (Table 2).
Distinct methodologies have been used in the assessment of
MSI in TGCT (Table 2), including the use of specific microsatel-
lite markers from mononucleotides to tetranucleotides, each of
which could lead to different results, as reported for EMAST, an
MSI form associated with tetranucleotide repeats (Devaraj et al.,
2010; Carethers et al., 2015). Herein, we used a validated
methodology that comprised five quasimonomorphic mononu-
cleotide repeat markers to identify MSI (NR-27, NR-21, NR-24,
BAT-25, and BAT-26) as previously described (Viana-Pereira
et al., 2011; Yamane et al., 2014; Campanella et al., 2015). BAT-
Table 1 Clinicopathological features of testicular germ cell tumor (TGCT)
valid cases
Patients
BRAF MSI
Characteristics N (%) N (%)
TGCT valid 132 133
Age (year)
Mean (SD) 30 (9.9) 30 (10.0)
Range 1–63 1–63
Histological group
Non-seminoma 90 (68.2) 91 (68.4)
Seminoma 42 (31.8) 42 (31.6)
Histology
Mixed tumor 53 (40.2) 54 (40.6)
Seminoma 42 (31.8) 42 (31.6)
Embryonal carcinoma 16 (12.1) 17 (12.8)
Yolk Sac tumor 10 (7.6) 9 (6.8)
Immature teratoma 6 (4.5) 6 (4.5)
Mature teratoma 3 (2.3) 3 (2.3)
Choriocarcinoma 2 (1.5) 2 (1.5)
Serum tumor markers (AJCC)
S0 18 (13.6) 17 (12.8)
S1 31 (23.5) 30 (22.6)
S2 38 (28.8) 37 (27.8)
S3 23 (17.4) 25 (18.8)
SX 22 (16.7) 24 (18)
Staging (AJCC)
I 28 (21.2) 28 (21.1)
IS 20 (15.2) 21 (15.8)
II 25 (18.9) 26 (19.5)
III 59 (44.7) 58 (43.6)
Chemosensitivity
Responsive 84 (63.6) 84 (63.2)
Refractory 20 (15.2) 21 (15.8)
No chemotherapy 28 (21.2) 28 (21.1)
IGCCCG risk
Good 31 (23.5) 31 (23.3)
Intermediate 17 (12.9) 17 (12.8)
Poor 27 (20.5) 27 (20.3)
Not applicable 48 (36.4) 49 (36.8)
Missing 9 (6.8) 9 (6.8)
SD: Standard deviation; AJCC: American Joint Committee on Cancer; IGCCCG:
International Germ Cell Cancer Cooperative Group.
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25, BAT-26 (mononucleotides) and D5S346, D2S123, D17S250
(dinucleotides) were classically recommended by Bethesda
panel for MSI evaluation until 2002 (Boland et al., 1998), when
an international consensus updated the recommendation and
recommended that dinucleotide repeats be substituted for
mononucleotide repeats because of improved sensitivity
(Buhard et al., 2004). We utilized this new recommended
methodology for this study – a methodology that has been
recently validated by our group in the Brazilian population
(Campanella et al., 2014).
Other potential causes of differing results may be associated
with tumor aggressiveness. Mayer et al. (2002) assessed 111
TGCT cases and 11 of these were refractory to treatment. The
authors found a higher rate of MSI in the refractory cases
compared to treatment-responsive cases (45 vs. 6%, p = 0.001).
It is noteworthy that among refractory cases, the MSI group
achieved better median progression free-survival (26 months
vs. 6 months, p = 0.05). Although, it is not clear how TGCT
was treated in both groups. One hundred unselected cases
from study by Mayer et al. were used later as a control cohort
in the study by Honecker et al. (2009) (Table 2). Velasco et al.
(2008) assessed the MMR enzyme expression and MSI in 162
TGCT patients, with a majority having seminomas. The
authors found a negative correlation between MSI and sur-
vival. However, the rate of advanced and high-risk disease was
unknown, which may lead to a misinterpretation of the results.
(A) (B)
Figure 1 Overall survival of refractory and responsive testicular germ cell tumors cases. (A) microsatellite instability sample; (B) BRAF mutation sample.
Table 2 Summary of studies assessing MSI in testicular germ cell tumors (TGCT)
Author, year Sample (N)
Total/Refractory
Age (years) Country MSI high (%)
Total/Refractory
MSI markers
Huddart et al. (1995) 29/NR NR United Kingdom 21/NA Dinucleotide (D1S216,D2S123, D16S303, D17S796)
and tetra- and tri-nucleotide repeats.
Lothe et al. (1995) 31/NR NR Norway, Finland and
Denmark
0/NA 32 microsatellite loci (dinucleotide repeats)
Faulkner & Friedlander
(2000)
24/NR NR Australia 0/NA 78 microsatellite loci (di- and tetra-nucleotide repeats)
Velasco et al. (2004) 118/NR 16–45 Chile 25/NA Mononucleotide (BAT25, BAT26) and dinucleotide
(D2S123, D3S1029, D3S1283, D3S1293, D9S66,
D9S113, LNSCA and TP53CA)
Sommerer et al. (2005) 62/0 NR Germany 6/NA Mononucleotide (BAT25, BAT26, BAT40) and dinucleotide
(D2S123, D5S346, MSH6)
Olasz et al. (2005) 51/15 17–60 Hungary 0/0 Mononucleotide (BAT25, BAT26) and dinucleotide
(D2S123, D5S346, D17S250)
Honecker et al. (2009) 135/35 14–66 Germany and Netherlands 7/26 Mononucletide (BAT25, BAT26, BATRII, BAT40) and
dinucleotide (D2S123, D5S346, D17S250, MSH6)
Mayer et al. (2011)a 12/NR 17–48 Germany and Netherlands 33/NA Mononucleotide (BAT25, BAT26) and dinucleotide
(D2S123, D5S346, D17S250)
Vladusic et al. (2014) 40/NR 17–60 Croatia 0/NA BAT-26 (mononucleaotides) and 8 microsatellite loci
(dinucleotide repeats)
Current study 133/20 1–63 Brazil and Portugal 0/0 Mononucleotide (NR-27, NR-21, NR-24, BAT-25, BAT-26)
NR: not reported; NA: not applicable. aLate relapses.
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Despite these data, Olasz et al. (2005) studied 15 cases of treat-
ment refractory and 36 treatment-responsive TGCT cases and
although they found MSI in 31.4% of patients, none of cases
was MSI-high and there was no correlation with any clinical
variable, including resistance to treatment. Interestingly, Piu-
lats et al. (2009) did not identify the MSI in a nude mice
model with xenografts of germ cell tumor refractory to
cisplatin.
Another biomarker analyzed in the present study was the
BRAF V600E mutation. Herein, we did not identify any case or
cell line harboring a BRAF mutation, in accordance with the
majority of the studies that addressed this issue after McIntyre
et al. (2005) (Table 3). Nevertheless, some authors have reported
BRAF mutations in TGCT, with a frequency up to 28% (Table 3).
Interestingly, Honecker et al. (2009) found that resistant tumors
had a higher incidence of BRAF V600E mutations compared with
unselected tumors (26 vs. 1%, p = 0.0001) and, for the first time,
a correlation between BRAF V600E and cisplatin resistance was
reported. Nevertheless, Piulats et al. also assessed BRAF muta-
tion status in 75 men with germ cell tumors; 84% of cases were
non-SE and one-third of all cases were refractory to cisplatin.
None of these cases exhibited a BRAF V600E mutation (Piulats
et al., 2010). More recently, Satpute et al. (2013) analyzed 59
germ-cell tumors, among these more than half were treatment-
refractory, and no BRAF mutations were identified. Additionally,
Feldman et al. (2014) found no BRAF mutations in 46 GCT
refractory cases, the largest number of refractory cases already
reported. Interestingly, the TCAM2 seminoma cell line was ini-
tially reported to exhibit a BRAF mutation (de Jong et al., 2008).
However, other studies did not corroborate these findings even
in other germ cell tumor cell lines (Goddard et al., 2010; Feld-
man et al., 2014).
Our study is a retrospective analysis and therefore has an
inherent selection bias. However, our data are consistent with
findings from other studies that show MSI and BRAF mutations
are not present in TGCT. This series of 150 cases is very hetero-
geneous and representative of several types of germ cell tumor
histologies, clinical staging, and response rates to chemotherapy.
The predominance of advanced disease and non-SE histologies
in our series differs from the classical literature, where semino-
mas and stage I disease are the most common (Ries et al., 2007).
Our hospital is a reference center for TGCT, and affiliated with
the Brazilian Childhood Germ Cell Tumor Study Group, a con-
sortium developed to standardize the diagnostic assessment and
multidisciplinary treatment of TGCT patients in Brazil (Lopes
et al., 2009). For this reason, our series might be biased by more
advanced cases. However, the several risk groups were well rep-
resented in the study.
In conclusion, contrasting to other solid tumors,
microsatellite instability and BRAF V600E mutation are not
present in testicular germ cell tumors, even in treatment-
refractory cases. It is necessary to target other pathways and
explore other aspects of genetics and epigenetics in TGCT to
better understand its biology and identify new theranostic
biomarkers.
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